Locations:
Search IconSearch
August 31, 2023/Cancer/News & Insight

CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

23-CNR-4185077-CQD-Hero-650×450

Emerging diagnostics, therapies and procedures are improving the outlook for patients with colorectal cancer, yet this rapidly changing treatment landscape can be confusing. Similarly, healthcare providers are confounded by high rates of colorectal cancer in patients under the age of 50. The 9th annual colorectal oncology course, held at Marco Island, Florida on October 6-7, 2023, will feature panel discussions and Q&As with noted specialists across surgery, radiation oncology and genomics managing this complex disease.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“This essential update on the latest treatment changes in colorectal cancer will provide a multidisciplinary approach that’s crucial for disease management,” says Alok Khorana, MD, Director, Gastrointestinal Malignancies Program at Cleveland Clinic Cancer Center. “The program also brings focus to diagnosing and treating young-onset colorectal cancer.”

This two-day program is ideal for oncologists, surgeons, radiation oncologists, nurses and other healthcare professionals with an interest in treating patients with colorectal cancer. “For clinicians who may be too busy to attend large conferences, this national symposium a convenient way to get up to speed on everything that’s new in treating this disease.”

In this in-depth symposium, learners will gain a detailed look at a wide range of topics, including:

  • Total neoadjuvant therapy and neoadjuvant chemotherapy
  • The role of genomics and circulating tumor DNA in treatment decisions
  • Patient case studies
  • Management disease recurrence and adverse events

The live event is designated for a maximum of 8.25 American Medical Association PRA Category 1 Credits™ and 8.25 American Nurses Credentialing Center contact hours.

Register now.

Advertisement

Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023/Cancer/News & Insight
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-CNR-4274330-CQD-Hero-650×450
October 18, 2023/Cancer/News & Insight
Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023/Cancer/News & Insight
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023/Cancer/News & Insight
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023/Cancer/News & Insight
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

outreach to underserved communities
June 2, 2023/Cancer/News & Insight
Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust

prostate cancer
Lutetium-PSMA for Metastatic Prostate Cancer (Podcast)

FDA-approved therapy offers promise for patients with castrate-resistant prostate cancer

Ad